No Waiver for Faricimab: CDSCO Panel Asks Roche to Conduct Phase III Trial in India
New Delhi: Roche Products (India) Pvt Ltd has been directed by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) to conduct a Phase III clinical trial in India for its drug Faricimab (VABYSMO), proposed for the additional indication of macular edema secondary to retinal vein occlusion (RVO).
The matter was re-deliberated in the 7th meeting of the SEC (Ophthalmology) held on 16th July 2025 at CDSCO headquarters in New Delhi. The proposal had earlier been discussed in the SEC meeting dated 19th December 2024, where the firm had requested a waiver for the local Phase III clinical trial.
During the latest meeting, the firm presented justification for the unmet need in India, along with long-term safety data from the global clinical trial for the proposed indication. Roche also reiterated its request for waiver of the local Phase III clinical trial, committing instead to conducting a Phase IV study in India for the proposed indication.
However, the committee noted that appropriate and adequate long-term safety data for the drug product is not available in the Indian population. Furthermore, it was observed that Roche has not yet conducted the Phase IV clinical trial in India for the already approved indications of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), which was an earlier regulatory requirement.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.